Pro-Pharmaceuticals: Notice on Obtaining a Notice of Approval for Drug Supplementary Applications
Prologis Pharmaceuticals: Announcement on the signing of a strategic cooperation framework agreement
Prologis Pharmaceutical: Announcement on foreign investment of subsidiary companies
Apeloa Pharmaceutical: Summary table of non-operating funds utilization and other related funds flow for the first half of the year.
Apeloa Pharmaceutical: Financial Report for the first half of 2024.
Apeloa Pharmaceutical: Announcement Regarding the Approval by the USA FDA for Products of our wholly-owned Subsidiary.
Prologis Pharmaceutical: Announcement on Cancelling Repurchase Shares, Reducing Registered Capital and Notifying Creditors
Prologis Pharmaceuticals: Legal Opinion of the 2023 Annual General Meeting of Shareholders
Pro-Pharmaceuticals: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Prologis Pharmaceuticals: Announcement on the signing of a strategic cooperation framework agreement
Prologis Pharmaceutical: Announcement on the extension of the term of the company's first employee stock ownership plan
Prologis Pharmaceuticals: Board of Directors Remuneration and Assessment Committee Rules (2024 Revision)
Pro-Pharmaceuticals: Special Meeting System for Independent Directors (established in 2024)
Prologis Pharmaceuticals: Amendments to the Articles of Association
Prologis Pharmaceuticals: Accounting Services Selection and Employment System (established in 2024)
Prologis Pharmaceuticals: Board Nomination Committee Rules of Procedure (2024 Revision)
Prologis Pharmaceuticals: Shareholder return plan for the next three years (2024-2026)
Prologis Pharmaceuticals: Rules of Work for the Audit Committee of the Board of Directors (2024 Revision)
Prologis Pharmaceuticals: Rules of Procedure for the Board of Directors (2024)
Prologis Pharmaceuticals: Announcement on Cancelling the Repurchase of Shares and Reducing Registered Capital
No Data
No Data